RightFit
RecruitingPhase 3

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 65 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how safe ponesimod is and how well it works for adults ages 18–65 with moderate-to-severe chronic plaque psoriasis. This is a long-lasting skin condition that causes thick, scaly patches. The study is open label, meaning participants and study staff know which drug is given.

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Adults ages 18–65.
  • Body mass index (BMI), a measure of weight compared with height, above 18 and below 40.
  • Psoriasis covers at least 10% of the body’s skin.
  • Psoriasis Area and Severity Index (PASI) score of at least 12, which measures how much skin is affected and how severe it is.
  • Physician’s Global Assessment (PGA) score of at least 3, a doctor’s rating of psoriasis severity.
  • Diagnosed with moderate-to-severe plaque psoriasis.

Who can't join

  • Having certain other forms of psoriasis: widespread red skin (generalized erythrodermic), widespread pus-filled bumps (generalized pustular or von Zumbusch), small drop-shaped spots (guttate), or psoriasis on the palms or soles (palmoplantar).
  • A past allergic reaction or known or major sensitivity to the study drug.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Male and female subjects aged 18-65 years, inclusive * BMI \>18 and \<40 * Minimum affected BSA of 10% * PASI score ≥ 12 * PGA ≥ 3 * Diagnosed with moderate-to-severe plaque psoriasis Exclusion Criteria: * Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis * History of an allergic reaction or known and/or significant sensitivity to study drug

Study sites (10)

AZ

CA

FL

IN

NC

NH

NY

TX

WA